Delphistem is a company headquartered in the United States.
Delphistem develops a stem cell-based therapy aimed at restoring natural insulin production in people with diabetes using a non-invasive, cost-effective, and scalable approach.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.